Beckley Psytech Ltd.. (2/23/21). "Press Release: Beckley Psytech Appoints Ex-pharma CEO as Chief Operating Officer".

	Organisation	Beckley Psytech Ltd.
	Group	Atai Beckley (AtaiBeckley) (Group)
	Organisation 2	Otsuka Pharmaceutical Europe Ltd. (OPEL)
	Group	Otsuka (Group)
	Product	psychopharmaceutical
	Product 2	psilocybin
	Person	Page, Andy (Beckley Psytech 202102– COO before Otsuka Pharmaceutical Europe + Janssen UK + SKB)

Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through psychedelic medicine, has appointed Andy Page as its Chief Operating Officer with immediate effect.

Page brings over 25 years’ experience working within global pharmaceutical and medtech organisations in strategic and operation roles. He started his career at SmithKline Beecham before joining Johnson & Johnson at Janssen UK in 1996, eventually going on to direct the go-to-market strategy for the Medical Devices & Diagnostics global surgery division across 105 countries in Europe, Middle East and Africa. He later joined Otsuka Pharmaceutical Europe in 2014, where he served as interim President and CEO from 2019 and built the foundation for a new vision and company strategy.

In his role at Beckley Psytech, Page will be responsible for initiating collaborations and co-developments with partners across the biotech and pharmaceutical industries. He will also lead projects to negotiate key research, development and licensing deals, and add further depth and expertise to the firm’s leadership team.

He joins the company at an exciting time, following the recent £14m capital raise from investors in December 2020, a string of high profile appointments to the Scientific Advisory Board, and authorisation in the UK for a ground-breaking clinical trial to explore the effects of psychedelic agent psilocybin for treating short-lasting unilateral neuralgiform headache attacks (SUNHA).

Andy Page, Chief Operating Officer at Beckley Psytech, says:

“Beckley Psytech and its team has a track record of pioneering, patient-centric drug development. The psychedelic area of research is full of possibilities, and I’m excited to be joining the company at such a pivotal time and to contribute on the delivery of innovative psychedelic medicines.

“For people living with severe psychiatric and neurological illnesses, there remains much to be done to improve and optimise treatment and deliver greater therapeutic options. The Beckley team is passionate about making a difference and creating new products to improve and transform lives, and that is inspiring to be part of.”

Record changed: 2024-08-24